However, when BCL6 was removed from the oncogenic backbone and replaced with MYC, we no longer saw strong enrichment for depletion of GNA13. This fits with the distribution of GNA13 mutations in human DLBCL, which are found predominantly in the EZB subtype described by Schmitz et al., which expresses the highest levels of BCL62. This evidence concerns the gene GNA13 and diffuse large B-cell lymphoma.